Section Arrow
Quote
RVPH.NASDAQ
- Reviva Pharmaceuticals Holdings
(Financial Status)
Quotes are at least 15-min delayed:2026/03/09 16:34 EDT
After Hours
Last
 2.9699
+0.0899 (+3.12%)
Bid
2.89
Ask
2.97
High 2.97 
Low 2.87 
Volume 5.01K 
Regular Hours (Closed)
Last
 2.88
-0.694 (-19.42%)
Day High 
3.5 
Prev. Close
3.574 
1-M High
6.14 
Volume 
480.66K 
Bid
2.89
Ask
2.97
Day Low
2.86 
Open
3.43 
1-M Low
3.4 
Market Cap 
20.88M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.37 
20-SMA 4.82 
50-SMA 5.71 
52-W High 24.5 
52-W Low 3.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.80/-0.24
Enterprise Value
20.88M
Balance Sheet
Book Value Per Share
0.78
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ANTXAN2 Therapeutics5.25+2.41+84.86%-- 
After Hours 5.1 -0.15 -2.86%
RLMDRelmada Therapeutics7.17+2.72+61.12%-- 
After Hours 6.77 -0.4 -5.58%
IOVAIovance Biotherapeutics5.41+0.275+5.36%-- 
After Hours 5.3635 -0.0465 -0.86%
IBRXImmunityBio8.45-0.2-2.31%-- 
After Hours 8.46 +0.01 +0.12%
QNCXQuince Therapeutics0.1065+0.0042+4.11%-- 
After Hours 0.1051 -0.0014 -1.31%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which isintended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.